Review



αs saa improved model fit  (Amprion Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Amprion Inc αs saa improved model fit
    Flow chart showing selection of individuals. This includes individuals who had both versions of <t>the</t> <t>αS‐SAA.</t> α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).
    αs Saa Improved Model Fit, supplied by Amprion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1s+saa+improved+model+fit/pmc13172763-117-5-3?v=Amprion+Inc
    Average 86 stars, based on 1 article reviews
    αs saa improved model fit - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties"

    Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

    Journal: Movement Disorders Clinical Practice

    doi: 10.1002/mdc3.70434

    Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).
    Figure Legend Snippet: Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).

    Techniques Used: Selection

    Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.
    Figure Legend Snippet: Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.

    Techniques Used:



    Similar Products

    αs saa improved model fit  (Amprion Inc)
    86
    Amprion Inc αs saa improved model fit
    Flow chart showing selection of individuals. This includes individuals who had both versions of <t>the</t> <t>αS‐SAA.</t> α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).
    αs Saa Improved Model Fit, supplied by Amprion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1s+saa+improved+model+fit/pmc13172763-117-5-3?v=Amprion+Inc
    Average 86 stars, based on 1 article reviews
    αs saa improved model fit - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).

    Journal: Movement Disorders Clinical Practice

    Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

    doi: 10.1002/mdc3.70434

    Figure Lengend Snippet: Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).

    Article Snippet: Fmax in the Amprion‐150 h αS‐SAA improved model fit for HVLT‐R delayed recall ( P = 0.02) and RDI (0.04), and GDS (0.03).

    Techniques: Selection

    Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.

    Journal: Movement Disorders Clinical Practice

    Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

    doi: 10.1002/mdc3.70434

    Figure Lengend Snippet: Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.

    Article Snippet: Fmax in the Amprion‐150 h αS‐SAA improved model fit for HVLT‐R delayed recall ( P = 0.02) and RDI (0.04), and GDS (0.03).

    Techniques: